Multiple near-term milestones for ExpreS2ion Biotechnologies
With an upcoming phase III readout and ongoing toxicology studies it is safe to say that ExpreS2ion Biotechnologies has an interesting year ahead. On top of that, new partnerships are formed to further strengthen the value of the portfolio. The company now seeks to raise 102 MSEK in a rights issue for the financing of.